Medical School · Year 1 · Respiratory · includes a quiz and discussion video

Lecture 12: Pleural Diseases

Unit 1.8: Respiratory System

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the anatomy and physiology of the pleural space
2. Differentiate transudative from exudative pleural effusions using Light's criteria
3. Describe the causes, evaluation, and management of pleural effusions
4. Explain the pathophysiology and management of pneumothorax
5. Describe pleural malignancies including mesothelioma
6. Explain procedures for diagnosis and management of pleural disease

Pleural Anatomy and Physiology

Understanding the normal structure and function of the pleural space provides the foundation for comprehending pleural diseases.

Pleural Membranes

The pleural space is a potential space bounded by two serous membranes. The visceral pleura is a thin membrane investing the lung surface, extending into the interlobar fissures. It receives blood supply from the bronchial circulation and lacks pain sensation. The parietal pleura lines the inner surface of the thoracic cavity, including the chest wall, diaphragm, and mediastinum. It receives blood supply from the intercostal arteries and is innervated by somatic nerves, making it sensitive to pain—the source of pleuritic chest pain.

Normal Pleural Fluid

The normal pleural space contains only 5-15 mL of fluid, serving as a lubricant to reduce friction during breathing. This fluid appears clear and pale yellow, with protein concentration less than 2 g/dL. The pH is slightly alkaline at 7.60-7.64. Cells present include mesothelial cells from the pleural surfaces and macrophages.

Fluid Dynamics

Pleural fluid homeostasis depends on Starling forces governing fluid movement across capillary membranes. Fluid formation occurs primarily from systemic capillaries in the parietal pleura, driven by hydrostatic pressure gradients. Absorption occurs through lymphatic stomata in the parietal pleura, which have enormous absorptive capacity—able to remove up to 500 mL per day under normal conditions. In steady state, production (approximately 0.1-0.2 mL/kg/hour) equals absorption.

Mechanisms of Effusion Formation

Pleural effusions develop when fluid accumulation exceeds removal capacity. Increased hydrostatic pressure, as in heart failure, drives excess fluid into the pleural space. Decreased oncotic pressure from hypoalbuminemia (nephrotic syndrome, cirrhosis) reduces the osmotic force retaining fluid in vessels. Increased capillary permeability from infection or malignancy allows protein-rich fluid to leak. Impaired lymphatic drainage, often from malignant obstruction, prevents normal fluid absorption. Transdiaphragmatic passage of ascitic fluid contributes to hepatic hydrothorax.

<image>Panel A: Coronal cross-section of the thorax with labeled pleural membranes: visceral pleura as a thin blue line covering the lung surface and extending into fissures, parietal pleura lining the chest wall with costal, mediastinal, and diaphragmatic portions labeled, and the potential pleural space between them. Panel B: Magnified insets showing blood supply with bronchial vessels to visceral pleura, intercostal vessels to parietal pleura, and lymphatic stomata on the parietal surface for fluid absorption. Panel C: Starling forces illustrated with arrows: hydrostatic pressure from systemic capillaries into the pleural space, oncotic pressure toward capillaries, and lymphatic drainage arrows showing fluid exit pathways. Panel D: Four mechanisms of effusion formation: increased hydrostatic pressure from heart failure, decreased oncotic pressure from hypoalbuminemia, increased capillary permeability from inflammation, and blocked lymphatic drainage from tumor obstruction.</image>

Classification of Pleural Effusions

The fundamental distinction in pleural effusion evaluation is between transudates and exudates, as this classification narrows the differential diagnosis and guides management.

Light's Criteria

Light's criteria, developed in 1972, remain the standard for distinguishing transudative from exudative effusions. An effusion is classified as an exudate if it meets any one of the following criteria: pleural fluid protein divided by serum protein greater than 0.5; pleural fluid LDH divided by serum LDH greater than 0.6; or pleural fluid LDH greater than two-thirds the upper limit of normal serum LDH. If none of these criteria are met, the effusion is a transudate.

Light's criteria are highly sensitive for exudates (98%) but less specific (approximately 80%). This means some transudates are misclassified as exudates, particularly in patients on diuretic therapy. When clinical suspicion strongly favors a transudative cause but Light's criteria suggest exudate, calculating the serum-to-pleural fluid albumin gradient (greater than 1.2 g/dL supports transudate) may help clarify the diagnosis.

Transudative Effusions

Transudates result from systemic factors altering hydrostatic or oncotic pressures, without pleural disease itself. The most common cause is congestive heart failure, where elevated left atrial pressure transmits to pulmonary veins and pleural capillaries. Hepatic hydrothorax occurs in cirrhosis as ascitic fluid passes through diaphragmatic defects, characteristically producing right-sided effusions. Nephrotic syndrome causes effusions through profound hypoalbuminemia. Atelectasis generates effusions by creating negative intrapleural pressure. Constrictive pericarditis elevates systemic venous pressures.

Exudative Effusions

Exudates result from pleural inflammation, increased capillary permeability, or impaired lymphatic drainage. Infectious causes include parapneumonic effusions (adjacent to pneumonia), empyema (pus in the pleural space), and tuberculous pleuritis. Malignancy causes effusions through direct pleural invasion, lymphatic obstruction, or mediastinal involvement; lung cancer, breast cancer, and lymphoma are the most common primaries. Inflammatory conditions include rheumatoid pleuritis and lupus pleuritis. Pulmonary embolism can produce either transudative or exudative effusions. Other causes include chylothorax (lymphatic leak), hemothorax, and drug-induced pleuritis.

<image>Panel A: Thoracentesis being performed with pleural fluid collected, leading to a laboratory panel showing protein and LDH values for both pleural fluid and serum with Light's criteria ratios calculated in three boxes. Panel B: Flowchart branching to transudate in a blue box when all Light's criteria are negative, with causes listed including congestive heart failure, cirrhosis, and nephrotic syndrome, illustrated with failing heart, cirrhotic liver, and kidneys with protein loss icons. Panel C: Flowchart branching to exudate in a red box when any Light's criterion is positive, with causes listed including infection, malignancy, pulmonary embolism, and inflammation, illustrated with bacteria, cancer cells, pulmonary artery clot, and autoimmune antibody icons. Panel D: Summary comparison of transudate versus exudate characteristics including protein ratio, LDH ratio, and absolute LDH thresholds defining each category.</image>

Clinical Evaluation of Pleural Effusion

Symptoms

The symptoms of pleural effusion depend on size, rate of accumulation, and underlying cause. Dyspnea develops when effusion size compromises lung expansion; slowly accumulating effusions may be asymptomatic until very large. Pleuritic chest pain—sharp, worsened by inspiration—indicates pleural inflammation and is more common with exudative than transudative effusions. A dry, nonproductive cough may result from pleural irritation or compression of airways. Symptoms of the underlying cause often dominate: fever in infection, weight loss in malignancy, peripheral edema in heart failure.

Physical Examination

Physical findings become apparent when effusion volume exceeds 300-500 mL. Dullness to percussion is present over the effusion, in contrast to resonance over normal lung. Breath sounds are diminished or absent over the fluid collection. Tactile fremitus is decreased because fluid attenuates vibration transmission. Egophony (E-to-A change) may be heard at the upper border of the effusion where compressed lung meets fluid. A pleural friction rub, a creaking or grating sound synchronous with breathing, indicates pleuritis and is heard early before significant fluid accumulates. With large effusions, the trachea may deviate away from the affected side.

Imaging

Chest radiography detects effusions larger than 200 mL on upright posteroanterior view, appearing as blunting of the costophrenic angle. The meniscus sign describes the concave upper border where fluid rises higher along the chest wall than centrally. Lateral decubitus views demonstrate layering of free-flowing fluid along the dependent chest wall and help quantify effusion size. Ultrasound is more sensitive than plain radiography, detecting effusions as small as 50 mL. It distinguishes free from loculated fluid, identifies septations, and guides thoracentesis. CT chest provides comprehensive evaluation of pleural thickening, loculations, underlying lung parenchyma, and mediastinal structures.

Thoracentesis Indications

Thoracentesis should be performed for new pleural effusions of unclear etiology to establish diagnosis. It is indicated when effusion in a patient with known cause fails to respond as expected, to exclude superimposed infection or malignancy. Large symptomatic effusions benefit from therapeutic thoracentesis for relief of dyspnea.

<image>Panel A: Posterior view of a patient with physical examination findings on the right hemithorax: dullness to percussion over the lower third in gray shading, decreased breath sounds with muted stethoscope waves, decreased tactile fremitus with diminished vibration lines, and egophony at the upper effusion border transition zone. Panel B: Tracheal deviation to the left from large effusion, with upright chest X-ray showing meniscus sign as the concave upper border of right-sided effusion. Panel C: Lateral decubitus view showing layering free-flowing fluid along the chest wall with measured thickness, and ultrasound image showing anechoic black fluid with lung atelectasis above it. Panel D: CT chest showing large right effusion with passive atelectasis of adjacent lung, and inset of thoracentesis technique with needle entering above the rib to avoid the neurovascular bundle.</image>

Pleural Fluid Analysis

Comprehensive analysis of pleural fluid provides diagnostic information far beyond the transudate-exudate distinction.

Routine Tests

Visual appearance offers immediate clues: bloody fluid suggests malignancy, trauma, or pulmonary embolism; turbid or purulent fluid indicates infection; milky fluid suggests chylothorax. Cell count with differential guides etiology interpretation. Protein and LDH are essential for Light's criteria. Glucose level is particularly useful: very low glucose (less than 30 mg/dL) indicates empyema, rheumatoid pleuritis, or malignancy; low glucose (30-60 mg/dL) suggests tuberculosis, lupus, or esophageal rupture. Pleural fluid pH below 7.20 in parapneumonic effusions indicates complicated effusion requiring drainage.

Additional Tests Based on Suspicion

When infection is suspected, Gram stain and bacterial culture are essential. Cytology examines for malignant cells; sensitivity is approximately 60% for a single sample, increasing to 80% with repeat thoracentesis. Triglyceride level greater than 110 mg/dL is diagnostic of chylothorax. Amylase is elevated in pancreatitis (salivary isoform) and esophageal rupture (salivary isoform plus low pH). Adenosine deaminase (ADA) greater than 40 U/L strongly suggests tuberculous pleuritis in endemic areas. Hematocrit more than 50% of serum hematocrit defines hemothorax. BNP may help identify heart failure when clinical picture is unclear.

Interpretation by Cell Differential

The predominant cell type narrows the differential. Neutrophil predominance indicates acute processes: bacterial infection, pulmonary embolism, early tuberculosis, or pancreatitis. Lymphocyte predominance (greater than 50%) suggests tuberculosis, malignancy, or rheumatoid effusion. Eosinophilia (greater than 10%) occurs when air or blood has been introduced to the pleural space, or with drug reactions, parasitic infections, or malignancy. Abundant mesothelial cells (greater than 5%) makes tuberculosis unlikely, as the granulomatous reaction typically prevents mesothelial cell sloughing.

<image>Panel A: Test tube with layered pleural fluid demonstrating possible appearances: clear yellow, bloody red, turbid gray, and milky white, each suggesting different etiologies. Panel B: Routine tests in blue section including appearance, cell count with differential, protein, LDH, glucose, and pH with reference values; special tests in green section including culture, cytology, triglycerides, amylase, ADA, and hematocrit. Panel C: Cell type interpretation guide showing neutrophils pointing to acute infection and PE, lymphocytes pointing to tuberculosis and malignancy, and eosinophils pointing to blood or air in the pleural space and drug reactions. Panel D: Glucose interpretation ladder showing very low glucose below 30 indicating empyema, rheumatoid arthritis, or malignancy; low glucose 30-60 indicating tuberculosis or lupus; and normal glucose for most other causes.</image>

Specific Causes of Pleural Effusion

Parapneumonic Effusion and Empyema

Parapneumonic effusions accompany bacterial pneumonia and progress through stages requiring escalating intervention. Simple parapneumonic effusions are sterile, exudative effusions with pH greater than 7.20 and glucose greater than 60 mg/dL; they respond to antibiotics alone without drainage. Complicated parapneumonic effusions are characterized by bacterial invasion with pH below 7.20, glucose below 60 mg/dL, positive Gram stain or culture, or loculations; these require chest tube drainage in addition to antibiotics. Empyema, defined as frank pus in the pleural space, represents the most advanced stage. Management includes chest tube drainage with antibiotics; intrapleural fibrinolytics (alteplase with dornase alfa) may help drain loculated collections. Surgical intervention (video-assisted thoracoscopic surgery for decortication) is needed when medical management fails.

Malignant Effusion

Malignant pleural effusions most commonly result from lung cancer, breast cancer, and lymphoma. Diagnosis requires cytologic confirmation, though sensitivity is only 60% from a single thoracentesis; repeat sampling or pleural biopsy increases yield. The presence of malignant effusion indicates advanced disease with poor prognosis (median survival measured in months). Management focuses on symptom relief: therapeutic thoracentesis provides temporary relief; pleurodesis (instillation of talc or other sclerosant to obliterate the pleural space) is 70-90% effective at preventing reaccumulation; indwelling pleural catheters allow patients to drain effusions at home and may achieve spontaneous pleurodesis over time.

Tuberculous Effusion

Tuberculous pleuritis presents as a lymphocyte-predominant exudate in patients with risk factors for TB. ADA greater than 40 U/L has high sensitivity and specificity in endemic regions. Acid-fast smear is rarely positive; culture yield is also limited. Pleural biopsy demonstrating granulomatous inflammation has the highest diagnostic yield. Treatment follows standard antituberculous therapy (RIPE regimen).

Chylothorax

Chylothorax results from disruption of the thoracic duct, allowing chyle (lymphatic fluid containing dietary fat) to accumulate in the pleural space. The classic milky appearance may be absent if the patient is fasting. Triglyceride level greater than 110 mg/dL is diagnostic. Causes include thoracic surgery, trauma, malignancy (particularly lymphoma), and rarely, idiopathic. Management includes NPO with total parenteral nutrition to reduce chyle flow, octreotide to decrease lymphatic flow, and surgical intervention (thoracic duct ligation) if conservative measures fail.

Hemothorax

Hemothorax is defined as pleural fluid hematocrit greater than 50% of serum hematocrit. Causes include trauma (most common), malignancy, pulmonary embolism, and iatrogenic injury. Management requires chest tube drainage both for therapeutic benefit and to prevent fibrothorax. Surgical exploration is indicated for massive initial output (greater than 1500 mL), ongoing bleeding (greater than 200 mL/hour for 2-4 hours), or hemodynamic instability.

<image>Panel A: Parapneumonic effusion three-stage progression: simple effusion with clear fluid and pH 7.3 responding to antibiotics, complicated effusion with turbid fluid, pH 7.0, and loculations requiring drainage, and empyema with pus and fibrous peel potentially requiring surgery. Panel B: Malignant effusion showing cancer cells from lung, breast, and lymphoma invading the pleura, cytology slide with malignant cells, and management options including thoracentesis, talc pleurodesis, and indwelling catheter. Panel C: Tuberculous effusion with predominant lymphocytes, ADA tube showing greater than 40, and granuloma histology with caseous necrosis; chylothorax with thoracic duct leak diagram, milky fluid, triglyceride level above 110, and treatments including NPO with TPN, octreotide, and surgery. Panel D: Hemothorax showing blood in the pleural space, hematocrit comparison with pleural greater than 50% of serum, trauma icon, and chest tube with blood drainage for evacuation.</image>

Management of Pleural Effusion

Therapeutic Thoracentesis

Large symptomatic effusions benefit from fluid removal regardless of etiology. The procedure provides rapid relief of dyspnea. Maximum removal should generally be limited to 1-1.5 liters per session to reduce the risk of re-expansion pulmonary edema, which can occur when the lung rapidly re-expands after prolonged compression. Ultrasound guidance reduces complications and improves success rates.

Chest Tube Drainage

Tube thoracostomy is indicated for complicated parapneumonic effusions with pH below 7.20 or positive culture, empyema, hemothorax requiring evacuation, and post-procedural air leaks. Larger bore tubes (24-36 French) are traditionally used for viscous fluid or blood, though small-bore catheters (8-14 French) are often adequate for less viscous collections and pneumothorax.

Pleurodesis

Pleurodesis aims to permanently obliterate the pleural space by inducing inflammation and fibrosis between the visceral and parietal pleura. Talc is the most effective sclerosant, with success rates of 70-90%. It can be instilled as a slurry through a chest tube or as poudrage (powder) during thoracoscopy. Other agents include doxycycline and bleomycin. Indications include recurrent malignant effusion and recurrent spontaneous pneumothorax. Requirements include adequate lung expansion (the lung must contact the parietal pleura for fusion to occur).

Indwelling Pleural Catheter

Indwelling pleural catheters provide an alternative to pleurodesis for recurrent malignant effusions, particularly in patients with trapped lung (lung unable to fully expand). The catheter is tunneled subcutaneously and remains in place, allowing the patient or caregiver to drain fluid at home every 1-2 days. Over time, approximately 50% of patients experience spontaneous pleurodesis, allowing catheter removal.

Surgery

Video-assisted thoracoscopic surgery (VATS) allows visualization of the pleural space for biopsy, lysis of adhesions, and decortication (removal of fibrous peel trapping the lung). Open thoracotomy is reserved for cases where VATS is insufficient.

<image>Panel A: Thoracentesis showing patient seated with ultrasound-guided needle insertion above the rib, syringe aspirating fluid with maximum 1 to 1.5 liter notation; chest tube diagram with tube entering the safe triangle connected to an underwater seal drainage system. Panel B: Pleurodesis with two methods shown: talc slurry mixed with saline injected through chest tube, and talc poudrage powder insufflated during thoracoscopy for pleural space obliteration. Panel C: Indwelling pleural catheter showing tunneled catheter diagram with external portion and home drainage into a vacuum bottle for recurrent effusions, particularly with trapped lung. Panel D: Surgical intervention with VATS showing three port sites marked on the chest, thoracoscope and instruments for visualization, and decortication specimen of thick fibrous peel, with indications listed below each intervention.</image>

Pneumothorax

Pneumothorax is the presence of air in the pleural space, causing partial or complete lung collapse.

Classification

Primary spontaneous pneumothorax occurs without apparent underlying lung disease, typically from rupture of a subpleural apical bleb. Secondary spontaneous pneumothorax occurs in patients with underlying lung disease, most commonly COPD, but also cystic fibrosis and Pneumocystis pneumonia. Traumatic pneumothorax results from penetrating or blunt chest trauma, or iatrogenic causes including central venous catheter placement, thoracentesis, and mechanical ventilation (barotrauma). Tension pneumothorax is a life-threatening condition in which a one-way valve mechanism allows air to enter the pleural space during inspiration but not escape during expiration, leading to progressive accumulation, mediastinal shift, and hemodynamic compromise.

Risk Factors for Primary Spontaneous Pneumothorax

The classic demographic is a tall, thin young male. Smoking increases risk 20-fold by inducing subpleural bulla formation. Peak incidence is between ages 15 and 35. Recurrence risk is approximately 30% after a first episode, higher with each subsequent event.

Clinical Features

Patients present with sudden onset of pleuritic chest pain on the affected side and dyspnea. Symptoms may be minimal with small pneumothorax or severe with tension physiology. Physical examination reveals decreased or absent breath sounds on the affected side, hyperresonance to percussion (in contrast to the dullness of effusion), and decreased tactile fremitus. With tension pneumothorax, tracheal deviation toward the contralateral side, hypotension, and tachycardia indicate impending cardiovascular collapse. Distended neck veins may be present.

<image>Panel A: Primary spontaneous pneumothorax showing young thin male silhouette with apical bleb rupturing, air in the pleural space, and partially collapsed lung; secondary spontaneous pneumothorax showing emphysematous lung with multiple bullae and more severe collapse. Panel B: Traumatic pneumothorax showing chest with rib fracture and knife icon with air entering through the chest wall; tension pneumothorax showing progressive air accumulation, mediastinal shift to the opposite side, and compressed IVC and heart. Panel C: Clinical findings on a patient figure including hyperresonance to percussion with tympanic sound waves, absent breath sounds with silent stethoscope, deviated trachea pointing away from the tension side, and distended neck veins with tachycardia and hypotension. Panel D: Classic demographics for primary spontaneous pneumothorax: tall thin body habitus, young age 15-35, and smoking icon with 20-fold risk increase label.</image>

Pneumothorax Management

Imaging

Upright inspiratory chest radiograph is the standard initial imaging. The visceral pleural line is visible as a thin white line with absence of lung markings peripheral to it. Expiratory imaging may enhance visibility by decreasing lung volume. CT chest is the most sensitive modality and is useful for detecting small pneumothoraces, evaluating for underlying lung disease (blebs, bullae), and differentiating pneumothorax from large bullae. Point-of-care ultrasound can rapidly diagnose pneumothorax by demonstrating absent lung sliding.

Size Estimation

Guidelines use different size thresholds. British Thoracic Society guidelines define large pneumothorax as greater than 2 cm between the lung margin and chest wall at the level of the hilum. American College of Chest Physicians guidelines use 3 cm from apex to cupola. Size estimation guides management intensity.

Management Approach

Small, asymptomatic primary spontaneous pneumothorax in stable patients may be managed with observation, supplemental oxygen (which accelerates nitrogen absorption and pleural air resorption), and serial chest radiographs. Large or symptomatic primary spontaneous pneumothorax requires intervention. Needle aspiration is a first-line option in many guidelines, with success rates of 50-80%. If aspiration fails or for larger pneumothoraces, chest tube placement is indicated. Secondary spontaneous pneumothorax is generally treated more aggressively than primary, as patients have less respiratory reserve; most require chest tube drainage regardless of size.

Tension Pneumothorax

Tension pneumothorax is a clinical diagnosis—treatment should not be delayed for imaging. The mechanism is a one-way valve allowing air entry during inspiration without exit during expiration. Progressive accumulation collapses the lung, shifts the mediastinum, kinks the vena cava, and impairs venous return. Clinical features include severe respiratory distress, hypotension, tachycardia, distended neck veins, tracheal deviation, and absent breath sounds. Immediate needle decompression is performed by inserting a large-bore needle into the second intercostal space at the midclavicular line (or the fifth intercostal space at the anterior axillary line). This temporizing measure is followed immediately by chest tube insertion.

Surgical Indications

Surgery (typically VATS with bullectomy and pleurodesis) is indicated for recurrent ipsilateral pneumothorax, bilateral pneumothorax, persistent air leak beyond 5-7 days, first episode in a patient with high-risk occupation (pilots, divers), and large visible blebs on imaging that pose ongoing risk.

<image>Panel A: Flowchart beginning with pneumothorax diagnosed, branching by type: primary spontaneous with size assessment of small 2 cm or less leading to observation and oxygen, and large greater than 2 cm leading to aspiration first-line with chest tube if aspiration fails; secondary spontaneous leading to chest tube given reduced reserve. Panel B: Tension pneumothorax in red emergency box showing immediate needle decompression at labeled anatomical sites of second intercostal space midclavicular line or fifth intercostal space anterior axillary line, followed by chest tube insertion. Panel C: Surgical intervention indications listed: recurrent pneumothorax, bilateral pneumothorax, persistent air leak beyond 5 days, and high-risk occupation shown with airplane and diving icons. Panel D: Imaging examples showing chest X-ray with visceral pleural line visible and absent lung markings beyond it, CT showing apical blebs, and ultrasound demonstrating absent lung sliding sign with A-lines without sliding.</image>

Pleural Malignancies

Mesothelioma

Malignant pleural mesothelioma is an aggressive neoplasm arising from mesothelial cells of the pleura. The dominant risk factor is asbestos exposure, with a characteristic latency period of 20-40 years between exposure and disease development. Occupations at risk include shipyard workers, insulation installers, and construction workers.

Histologic subtypes include epithelioid (best prognosis), sarcomatoid (worst prognosis), and biphasic (mixed features). Patients present with progressive dyspnea, chest pain, and pleural effusion. Imaging shows pleural thickening that may encase and constrict the lung. Diagnosis requires tissue biopsy, preferably thoracoscopic for adequate sampling. Immunohistochemistry helps distinguish mesothelioma from adenocarcinoma: mesothelioma is positive for calretinin and WT1, negative for CEA and TTF-1 (the opposite pattern of adenocarcinoma).

Treatment is multimodal for selected patients, combining surgery (pleurectomy/decortication or extrapleural pneumonectomy), chemotherapy (pemetrexed plus cisplatin), and radiation. Prognosis remains poor, with median survival of 12-18 months even with aggressive therapy.

Metastatic Pleural Disease

The pleura is a common site of metastatic involvement. The most frequent primary sites are lung cancer, breast cancer, lymphoma, and ovarian cancer. Diagnosis is made by pleural fluid cytology or pleural biopsy. Management is palliative, focusing on symptom control through drainage and pleurodesis.

Asbestos-Related Pleural Disease Spectrum

Asbestos exposure produces a spectrum of pleural abnormalities. Pleural plaques are the most common manifestation—benign, often calcified areas of parietal pleural thickening. They are markers of exposure without malignant potential and require no treatment. Benign asbestos effusion is a self-limited exudative effusion occurring within 10 years of exposure; it is a diagnosis of exclusion requiring ruling out mesothelioma. Diffuse pleural thickening is more extensive than plaques and may cause restrictive physiology. Mesothelioma represents the malignant end of the spectrum.

<image>Panel A: Mesothelioma timeline showing asbestos exposure with fibers entering the lung and shipyard workers 20-40 years before disease onset, with CT showing circumferential pleural thickening encasing and compressing the lung. Panel B: Histology comparison of mesothelioma subtypes: epithelioid with orderly cells positive for calretinin and WT1, sarcomatoid with spindle cells, and biphasic with mixed features; immunohistochemistry panel showing positive markers calretinin and WT1 and negative markers CEA and TTF-1 differentiating from adenocarcinoma. Panel C: Treatment icons including surgery, chemotherapy infusion, and radiation with survival curve showing median 12-18 months even with aggressive multimodal therapy. Panel D: Asbestos-related pleural disease spectrum as a progression: pleural plaques as calcified benign areas on parietal pleura, benign asbestos effusion with self-limited course, diffuse pleural thickening with restrictive spirometry pattern, and mesothelioma as the malignant endpoint.</image>

Pleural Procedures

Thoracentesis

Thoracentesis is performed for diagnostic or therapeutic purposes. The patient is positioned upright with arms resting forward. Site selection is guided by ultrasound, which identifies the effusion, marks depth, and avoids underlying structures. The needle insertion site is above the rib to avoid the neurovascular bundle running along the inferior rib margin. Diagnostic samples require minimal volume (30-50 mL); therapeutic drainage may remove 1-1.5 liters. Complications include pneumothorax (reduced with ultrasound guidance), bleeding, and re-expansion pulmonary edema.

Chest Tube (Tube Thoracostomy)

Chest tubes drain air, blood, or pus from the pleural space. Size selection depends on the indication: small-bore catheters (8-14 French) are often adequate for pneumothorax and simple effusions, while large-bore tubes (24-36 French) are preferred for hemothorax and empyema. The insertion site is typically the fourth or fifth intercostal space anterior to the midaxillary line, within the "safe triangle" bounded by the lateral border of pectoralis major, lateral border of latissimus dorsi, and horizontal line at nipple level. Tubes are connected to an underwater seal drainage system or to suction.

Pleuroscopy and Thoracoscopy

Medical pleuroscopy (performed under local anesthesia and sedation) or video-assisted thoracoscopic surgery (VATS, performed under general anesthesia) allows direct visualization of the pleural space. Indications include undiagnosed exudative effusion where cytology is negative, staging of malignancy, therapeutic procedures (pleurodesis, drainage of loculated fluid, lysis of adhesions), and management of recurrent pneumothorax.

Pleural Biopsy

When pleural fluid analysis fails to establish diagnosis, tissue biopsy may be required. Image-guided percutaneous needle biopsy is appropriate for focal pleural lesions. Thoracoscopic biopsy has the highest diagnostic yield (greater than 90% for malignancy and tuberculosis) as it allows visualization and targeted sampling of abnormal areas.

<image>Panel A: Thoracentesis showing patient seated and leaning forward, ultrasound probe on the back identifying effusion with depth marked, needle insertion point above the rib with neurovascular bundle labeled below, and syringe withdrawing fluid. Panel B: Chest tube insertion showing anterior-lateral view of chest with the safe triangle outlined by pectoralis border, latissimus border, and nipple line, fourth intercostal space marked, insertion technique with incision and blunt dissection, and tube connected to underwater seal with bubbling. Panel C: Pleuroscopy showing patient in lateral decubitus position with port sites marked, thoracoscopic view of pleural surface with nodules and biopsy forceps sampling tissue, and additional ports for instruments. Panel D: Key procedural pearls listed for each intervention: thoracentesis with ultrasound guidance reducing pneumothorax risk, chest tube with safe triangle avoiding vital structures, and pleuroscopy providing the highest diagnostic yield for undiagnosed effusions.</image>

Summary

The pleural space is a potential space between visceral and parietal pleura containing minimal fluid under normal conditions. Effusions develop from imbalanced Starling forces or impaired lymphatic drainage.

Light's criteria distinguish transudates (protein ratio ≤0.5, LDH ratio ≤0.6, LDH ≤2/3 upper normal) from exudates (any criterion exceeded). Transudates result from systemic conditions (CHF, cirrhosis); exudates result from pleural pathology (infection, malignancy, inflammation).

Parapneumonic effusions progress from simple (antibiotics alone) to complicated (require drainage) to empyema (pus, may require surgery).

Malignant effusions have poor prognosis; management focuses on symptom relief through thoracentesis, pleurodesis, or indwelling catheter.

Chylothorax is diagnosed by triglycerides greater than 110 mg/dL and results from thoracic duct injury.

Pneumothorax classification includes primary spontaneous (young thin males, blebs), secondary spontaneous (underlying lung disease), traumatic, and tension (medical emergency requiring immediate decompression).

Tension pneumothorax causes mediastinal shift and cardiovascular compromise; treatment is immediate needle decompression followed by chest tube.

Mesothelioma results from asbestos exposure with 20-40 year latency; it is calretinin-positive and has poor prognosis.

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown